Recently, a phase I clinical trial was initiated to evaluate the best dose, possible benefits, and side effects of interleukin-18-secreting autologous anti-CD19 CAR T-Cells (huCART19-IL18) in treating patients with non-Hodgkin's lymphoma (NHL), CLL, and ALL. Here, CD19 is linked to non-Hodgkin lymphoma.